Creso Pharma Limited
COPHF · OTC
12/31/2023 | 6/30/2023 | 12/31/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $1 | – | $1 | – |
| Short-Term Investments | $0 | – | $0 | – |
| Receivables | $3 | – | $3 | – |
| Inventory | $1 | – | $6 | – |
| Other Curr. Assets | $0 | – | $0 | – |
| Total Curr. Assets | $6 | – | $10 | – |
| Property Plant & Equip (Net) | $10 | – | $10 | – |
| Goodwill | $3 | – | $0 | – |
| Intangibles | $0 | – | $16 | – |
| Long-Term Investments | $0 | – | $0 | – |
| Tax Assets | $0 | – | $0 | – |
| Other NC Assets | $0 | – | $2 | – |
| Total NC Assets | $14 | – | $28 | – |
| Other Assets | $0 | – | $0 | – |
| Total Assets | $19 | – | $38 | – |
| Liabilities | – | – | – | – |
| Payables | $9 | – | $3 | – |
| Short-Term Debt | $10 | – | $7 | – |
| Tax Payable | $0 | – | $0 | – |
| Deferred Revenue | $0 | – | $0 | – |
| Other Curr. Liab. | $4 | – | $0 | – |
| Total Curr. Liab. | $23 | – | $16 | – |
| LT Debt | $0 | – | $0 | – |
| Deferred Rev, NC | $0 | – | $0 | – |
| Deferred Tax Liab, NC | $0 | – | $0 | – |
| Other NC Liab. | $0 | – | $11 | – |
| Total NC Liab. | $0 | – | $11 | – |
| Other Liabilities | $0 | – | -$11 | – |
| Cap. Leases | $0 | – | $0 | – |
| Total Liabilities | $23 | – | $16 | – |
| Equity | – | – | – | – |
| Pref Stock | $0 | – | $0 | – |
| Common Stock | $150 | – | $128 | – |
| Retained Earnings | -$170 | – | -$127 | – |
| AOCI | $15 | – | $21 | – |
| Other Equity | $0 | – | $0 | – |
| Total Equity | -$4 | – | $22 | – |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | – | $0 | – |
| Total Liab. & Tot. Equity | $19 | – | $38 | – |
| Net Debt | $9 | $0 | $5 | $0 |